ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Down 42.6% in December

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 360,300 shares, a decline of 42.6% from the December 15th total of 628,000 shares. Based on an average daily volume of 266,100 shares, the short-interest ratio is currently 1.4 days. Approximately 3.2% of the company’s stock are short sold.

ABVC BioPharma Stock Performance

Shares of ABVC BioPharma stock opened at $0.55 on Thursday. The firm’s 50-day simple moving average is $0.54 and its 200-day simple moving average is $0.63. ABVC BioPharma has a 1 year low of $0.41 and a 1 year high of $1.73. The firm has a market cap of $7.07 million, a PE ratio of -0.63 and a beta of 0.70.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.